This company has been marked as potentially delisted and may not be actively trading. Third Harmonic Bio (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock THRD vs. NEO, SYRE, MDXG, PHVS, MLYS, NRIX, RCUS, PRAX, GERN, and ORICShould you be buying Third Harmonic Bio stock or one of its competitors? The main competitors of Third Harmonic Bio include NeoGenomics (NEO), Spyre Therapeutics (SYRE), MiMedx Group (MDXG), Pharvaris (PHVS), Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Praxis Precision Medicines (PRAX), Geron (GERN), and Oric Pharmaceuticals (ORIC). These companies are all part of the "med - biomed/gene" industry. Third Harmonic Bio vs. Its Competitors NeoGenomics Spyre Therapeutics MiMedx Group Pharvaris Mineralys Therapeutics Nurix Therapeutics Arcus Biosciences Praxis Precision Medicines Geron Oric Pharmaceuticals Third Harmonic Bio (NASDAQ:THRD) and NeoGenomics (NASDAQ:NEO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership. Does the media prefer THRD or NEO? In the previous week, NeoGenomics had 6 more articles in the media than Third Harmonic Bio. MarketBeat recorded 7 mentions for NeoGenomics and 1 mentions for Third Harmonic Bio. Third Harmonic Bio's average media sentiment score of 0.00 equaled NeoGenomics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Third Harmonic Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, THRD or NEO? Third Harmonic Bio has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Which has better earnings and valuation, THRD or NEO? Third Harmonic Bio has higher earnings, but lower revenue than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Third Harmonic Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioThird Harmonic BioN/AN/A-$45.47M-$0.62-8.76NeoGenomics$660.57M1.48-$78.73M-$0.61-12.48 Do institutionals and insiders have more ownership in THRD or NEO? 94.0% of Third Harmonic Bio shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 7.8% of Third Harmonic Bio shares are held by company insiders. Comparatively, 2.4% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is THRD or NEO more profitable? Third Harmonic Bio has a net margin of 0.00% compared to NeoGenomics' net margin of -11.54%. NeoGenomics' return on equity of -2.21% beat Third Harmonic Bio's return on equity.Company Net Margins Return on Equity Return on Assets Third Harmonic BioN/A -19.27% -18.67% NeoGenomics -11.54%-2.21%-1.22% Do analysts recommend THRD or NEO? Third Harmonic Bio presently has a consensus target price of $5.00, suggesting a potential downside of 7.92%. NeoGenomics has a consensus target price of $13.83, suggesting a potential upside of 81.66%. Given NeoGenomics' stronger consensus rating and higher probable upside, analysts clearly believe NeoGenomics is more favorable than Third Harmonic Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Third Harmonic Bio 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00NeoGenomics 0 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.45 SummaryNeoGenomics beats Third Harmonic Bio on 9 of the 14 factors compared between the two stocks. Get Third Harmonic Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricThird Harmonic BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.06M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-4.4121.7127.6620.25Price / SalesN/A281.11416.07118.18Price / CashN/A42.7336.8958.07Price / Book0.867.518.035.67Net Income-$45.47M-$55.14M$3.18B$249.21M Third Harmonic Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDThird Harmonic Bio0.7184 of 5 stars$5.43+0.2%$5.00-7.9%-54.6%$245.06MN/A-4.41N/ANews CoverageNEONeoGenomics3.6737 of 5 stars$7.41+1.4%$13.83+86.7%-44.5%$953.67M$660.57M-12.152,200SYRESpyre Therapeutics1.581 of 5 stars$15.49+3.5%$53.40+244.7%-38.5%$933.74M$890K-4.1173News CoverageMDXGMiMedx Group3.4453 of 5 stars$6.22+1.8%$12.50+101.0%-7.8%$918.69M$348.88M23.04870PHVSPharvaris1.5715 of 5 stars$17.25-2.0%$36.20+109.9%+10.4%$902.00MN/A-5.7330Positive NewsGap UpMLYSMineralys Therapeutics2.1643 of 5 stars$13.70+1.3%$32.25+135.4%+19.5%$892.90MN/A-3.6728NRIXNurix Therapeutics1.6398 of 5 stars$11.71+2.8%$30.18+157.7%-34.4%$892.77M$54.55M-4.18300Trending NewsUpcoming EarningsAnalyst RevisionRCUSArcus Biosciences2.7908 of 5 stars$8.35+2.6%$21.29+154.9%-41.1%$884.18M$258M-1.99500PRAXPraxis Precision Medicines3.1598 of 5 stars$43.17+2.7%$92.11+113.4%+18.2%$879.37M$8.55M-4.03110GERNGeron2.7111 of 5 stars$1.38-2.1%$5.06+266.8%-67.3%$878.95M$76.99M-6.5770ORICOric Pharmaceuticals4.161 of 5 stars$10.14-0.1%$19.17+89.0%+43.2%$864.13MN/A-5.4280 Related Companies and Tools Related Companies NeoGenomics Competitors Spyre Therapeutics Competitors MiMedx Group Competitors Pharvaris Competitors Mineralys Therapeutics Competitors Nurix Therapeutics Competitors Arcus Biosciences Competitors Praxis Precision Medicines Competitors Geron Competitors Oric Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THRD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Third Harmonic Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Third Harmonic Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THRD Stock Alerts